ArticleJournal of medical biochemistry2026
Hyperthyroidism complicated with diabetes mellitus using the health promotion model: changes in thyroid hormones, glucose-lipid metabolism, and inflammatory markers.
Article in Journal of medical biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: To investigate the effects of a Health Promotion Model (HPM)-based comprehensive intervention on thyroid hormones, glucose-lipid metabolism, and inflammatory markers in patients with hyperthyroidism (HT) complicated by diabetes mellitus (DM), and to elucidate the potential mechanisms underlying these effects. Methods: A total of 142 patients diagnosed with HT and DM between January 2024 and January 2025 were enrolled. Participants were divided into two groups: the HPM group (n = 64), which received a structured HPM-based intervention, and the conventional group (n = 78), which underwent standard management. Laboratory assessments were conducted before and after the intervention to evaluate thyroid hormones (FT3, FT4, TSH), glucose-lipid metabolism parameters (fasting plasma glucose [FPG], glycated hemoglobin [HbA1c], total cholesterol [TC], triglycerides [TG]), and inflammatory markers (high-sensitivity C-reactive protein [hs-CRP], interleukin-1p/6 [IL-1 b/IL-6]). Data were analyzed using SPSS 24.0. Results: Compared to the conventional group, the HPM group exhibited significantly greater improvements in thyroid function, with more pronounced reductions in FT3 and FT4 (P< 0.001) and a greater increase in TSH (P< 0.001). Regarding glucose-lipid metabolism, significantly larger decreases in FPG, HbA1c, TC, and TG were identified in the HPM group (P< 0.001). Among inflammatory markers, the HPM group showed significant reductions in hs-CRP IL-1 b, IL-6, MIP-1a, and MMP-9 (P< 0.001), whereas the conventional group only exhibited improvements in hs-CRP and IL-1 b (P< 0.001). Conclusions: The HPM-based intervention effectively disrupts the 'thyroid-glycolipid-inflammation' axis in HT-DM comorbidity through cognitive restructuring, behavioral modification, and environmental support.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.